Stay updated on Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial
Sign up to get notified when there's something new on the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page.

Latest updates to the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.3.3 was added to the record history, and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe record history now lists revision v3.3.2 and removes v3.2.0.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoved the general government funding and operating status notice from the page, and the trial record content remains unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check54 days agoChange DetectedStudy Status was updated in version 2 on 2021-10-25. Recruitment Status was updated in version 3 on 2023-07-26.SummaryDifference0.1%

- Check83 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference13%

- Check90 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.3%

Stay in the know with updates to Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page.